It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for Sarepta Therapeutics Inc. (SRPT) shows that investor sentiment remained same, with the stock’s consolidated last price remained same by $0.00, or 0.00%, to $120.13. The Sarepta Therapeutics Inc. has recorded 124,668 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues.
Sarepta Therapeutics Inc. is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $120.13 and fluctuated between $122.37 as its day high and $118.78 as its day low. The current market capitalization of Sarepta Therapeutics Inc. is $10.49B. A total of 0.91 million shares were traded on the day, compared to an average of 946.46K shares.
Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, SRPT has seen 0 BUY and 2 SELL insider trades, representing the acquisition of 0 and the disposition of 5,069 shares. Over the last 12 months, there were 17 BUYs and 12 SELLs from insiders. Insiders purchased 162,804 shares during that period but sold 11,626.
In the most recent transaction, Mayo Stephen sold 858 shares of SRPT for 109.92 per share on Nov 17. After the transaction, the Director now owns 6,387 company shares. In a previous transaction on Sep 14, Chambers Michael Andrew bought 57,100 shares at 104.43 per share. SRPT shares that Director owns now total 108,178.
Among the insiders who bought shares, Chambers Michael Andrew acquired of 46,170 shares on Aug 19 at a per-share price of $108.28. This resulted in the Director holding 51,078 shares of SRPT after the transaction.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for SRPT in the last 3 months, the mean price target is $149.45 with high estimates of $204.00 and low estimates of $108.00. In terms of 52-week highs and lows, SRPT has a high of $134.08 and a low of $61.28.
As of this writing, SRPT has an earnings estimate of -$1.43 per share for the current quarter. EPS was calculated based on a consensus of 13 estimates, with a high estimate of -$0.81 per share and a lower estimate of -$2.05. The company reported an EPS of -$1.2 in the last quarter, which was 5.50% higher than expectations of -$1.27.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information.
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 21 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for SRPT is Sell with a score of 4.47. A total of 15 analysts rated the stock as Buy while 2 rated it as Overweight while 4 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.